...GlaxoSmithKline Plc, talks with Bloomberg's Francine Lacqua from London about first-quarter earnings, the company's drugs Avandia, Tykerb and Cervarix, and Glaxo's acquisition of Sirtris ...
7 months ago
Bloomberg - Financial News
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
...GlaxoSmithKline Plc, talks with Bloomberg's Nina de Roy and Rishaad Salamat from Middlesex, England, about the safety of diabetes drug Avandia, the outlook for new products and second-quarter ...
a year ago
Bloomberg - Financial News
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
...GlaxoSmithKline Plc, talks with Bloomberg's Ellen Braitman from Washington about the safety of the company's Avandia diabetes drug. Glaxo representatives and officials of the U.S. Food and Drug ...
a year ago
Bloomberg - Financial News
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
Jeremy Batstone-Carr, an equity strategist at Charles Stanley, talks with Bloomberg's Mark Barton in London about the outlook for GlaxoSmithKline Plc's third-quarter earnings to be released today and its possible strategy under chief executive officer-designate Andrew Witty, who will succeed CEO Jean-Pierre Garnier in May. GlaxoSmithKline is Europe's largest drugmaker. (Source: Bloomberg)
a year ago
Bloomberg - Financial News
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to: